Israel is a notable contributor in the global medical device industry, with innovations in imaging systems, surgical robots, and diagnostic equipment.

According to a 2024 report by PwC and IATI, 70 new life sciences startups were launched in Israel last year, with 27 focused on medical devices.

Despite a tough year and ongoing security challenges, the sector saw impressive momentum. Exits and IPOs totaled US$1.4 billion, driven largely by medical device companies.

Global corporations like Medtronic and Johnson & Johnson have R&D centers in Israel. These centers, along with returning Israeli executives familiar with the US market, are fueling startup growth and technological advances.

Their efficiency and understanding of US healthcare regulations make Israel a hub for medical device innovation.

🔗 Source: Calcalist

🧠 Food for thought

1️⃣ Immigration and military experience created Israel’s medtech foundation

Israel’s medical device sector owes much of its success to a unique combination of human capital influxes and institutional knowledge transfer.

The massive immigration of Russian scientists and engineers in the 1990s significantly expanded Israel’s technical expertise in mathematics and medical electronics, providing specialized skills that became foundational to the industry 1.

This scientific talent pool combined with military technology applications, where many founders gained experience developing sophisticated systems under pressure, created a powerful innovation ecosystem 1.

The country’s commitment to R&D is exceptional, spending 4.3% of GDP ($12.7 billion annually) on research, the highest intensity globally according to Bloomberg’s 2019 Innovation Index 1.

Unlike many innovation hubs, Israel’s medtech sector operates with remarkable efficiency. Many successful companies employ only small teams, allowing for focused development with minimal overhead 2.

2️⃣ Regulatory expertise creates competitive advantage in global markets

Israeli medical device companies have developed sophisticated knowledge of international regulatory frameworks that provides strategic market advantages.

The significant differences between FDA and EU classification systems, with the FDA’s three risk-based categories versus the EU’s four categories based on device characteristics, create complex market entry challenges that Israeli firms have learned to navigate effectively 3.